Overview

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
A phase 3 study to evaluate efficacy and safety of AGSAVI
Phase:
Phase 3
Details
Lead Sponsor:
Ahn-Gook Pharmaceuticals Co.,Ltd
Treatments:
Amlodipine
Indapamide
Niacin
Valsartan